GE Healthcare and Telix make some strides in prostate cancer imaging
Category: #health  By Mateen Dalal  Date: 2019-10-15
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

GE Healthcare and Telix make some strides in prostate cancer imaging

Prostate cancer is one of the leading causes of deaths among men in the U.S. On an average, 1 out of 9 men are diagnosed with prostate cancer in their lifetime. Currently, there are several treatments which can prevent this cancer or slow down its symptoms, but there is no definitive therapy that could eradicate it completely. However, several pharma companies are making some progress in this sector.

Telix Pharmaceuticals Limited, a clinical-stage biopharmaceutical company, recently made some developments when it announced that it has completed the integration of its regulatory package for TLX591-CDx with GE Healthcare’s cyclotron-based 68Ga (gallium) production data for the imaging of prostatic carcinoma with PET (Positron Emission Tomography).

According to reliable sources, both the firms entered into a partnership agreement to check 68Ga on the PETtrace® cyclotron with Telix’s illumet™ prostate imaging product, as well as to allow the data to be added to the company’s product dossier.

Reportedly, the validation was completed successfully, as for the data, it was shown to the regulators as a part of the company’s marketing authorization preparation in Europe and the U.S.

Speaking on the move, Dr. Bernard Lambert, President, Telix USA, said that the venture’s validation data needed for its regulatory submissions were highly productive. Moreover, the PETtrace® cyclotron platform possesses huge potential for augmenting the supply chain for 68Ga, which would be necessary for PSMA as well as an entire class of PET radiopharmaceuticals developing across the globe.

Earlier this year, Telix was also in headlines when it revealed that it had obtained and ethics and regulatory approvals to initiate the ENHANCING study with GenesisCare Pty Ltd.

For the record, the study focused on comparing the expression of PSMA (prostate-specific membrane antigen), after and before the treatment along with enzalutamide (Xtandi®). It was planned to be conducted on a total of 40 Australian men who had progressive metastatic prostate cancer and were in line to get second-line androgen-deprivation therapy.
 

Source Credit: https://www.globenewswire.com/news-release/2019/10/13/1928865/0/en/Telix-Pharmaceuticals-and-GE-Healthcare-Maximising-68Ga-Supply-for-Prostate-Cancer-Imaging.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...

Tata Motors records 25% jump in global sales in second quarter of 2021

Tata Motors records 25% jump in global sales in second quarter of 2021

By Mateen Dalal

The automaker’s annual wholesale growth has been around 24%. The company saw a 10% rise in passenger car sales during Q2 2021, as compared to the same period in 2020. Tata Motors Limited reported substantial growth in Q2 2021, with its glo...